Inhibikase Therapeutics Stock Buy Hold or Sell Recommendation
| IKT Stock | USD 2.92 0.19 6.96% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Inhibikase Therapeutics is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Inhibikase Therapeutics given historical horizon and risk tolerance towards Inhibikase Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Inhibikase Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Inhibikase Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase Therapeutics guide. Note, we conduct extensive research on individual companies such as Inhibikase and provide practical buy, sell, or hold advice based on investors' constraints. Inhibikase Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
Inhibikase |
Execute Inhibikase Therapeutics Buy or Sell Advice
The Inhibikase recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Inhibikase Therapeutics. Macroaxis does not own or have any residual interests in Inhibikase Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Inhibikase Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Solid | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Inhibikase Therapeutics Trading Alerts and Improvement Suggestions
| Inhibikase Therapeutics is way too risky over 90 days horizon | |
| Inhibikase Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 260.5 K. Reported Net Loss for the year was (19.03 M) with loss before taxes, overhead, and interest of (8.26 M). | |
| Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Inhibikase Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Inhibikase Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha |
Inhibikase Therapeutics Returns Distribution Density
The distribution of Inhibikase Therapeutics' historical returns is an attempt to chart the uncertainty of Inhibikase Therapeutics' future price movements. The chart of the probability distribution of Inhibikase Therapeutics daily returns describes the distribution of returns around its average expected value. We use Inhibikase Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Inhibikase Therapeutics returns is essential to provide solid investment advice for Inhibikase Therapeutics.
| Mean Return | 1.36 | Value At Risk | -9.09 | Potential Upside | 14.93 | Standard Deviation | 6.74 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Inhibikase Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Inhibikase Stock Institutional Investors
The Inhibikase Therapeutics' institutional investors refer to entities that pool money to purchase Inhibikase Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Redmond Asset Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 626.5 K | Blair William & Co | 2024-06-30 | 116.1 K | Geode Capital Management, Llc | 2024-09-30 | 50.1 K | Renaissance Technologies Corp | 2024-09-30 | 19.9 K | Vanguard Group Inc | 2024-09-30 | 16.7 K | State Street Corp | 2024-06-30 | 10.1 K |
Inhibikase Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Borrowings | (26.3K) | (22.8K) | 272.8K | (42.5K) | (48.9K) | (46.5K) | |
| Change To Netincome | 1.4M | 2.2M | 2.2M | 2.3M | 2.6M | 1.6M | |
| Change In Cash | (361.1K) | 13.9M | 26.8M | (33.6M) | 2.0M | 1.0M | |
| Net Income | (5.7M) | (2.8M) | (14.8M) | (18.1M) | (19.0M) | (18.1M) | |
| End Period Cash Flow | 18.5K | 14.0M | 40.8M | 7.2M | 9.2M | 11.2M | |
| Free Cash Flow | (338.3K) | (1.1M) | (14.3M) | (17.6M) | (18.1M) | (17.2M) | |
| Other Non Cash Items | 2.3M | 1.6M | 721.6K | 67K | 31.5K | 30.0K |
Inhibikase Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Inhibikase Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Inhibikase Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Inhibikase stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.14 | |
β | Beta against Dow Jones | 1.68 | |
σ | Overall volatility | 6.86 | |
Ir | Information ratio | 0.18 |
Inhibikase Therapeutics Volatility Alert
Inhibikase Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inhibikase Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inhibikase Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Inhibikase Therapeutics Fundamentals Vs Peers
Comparing Inhibikase Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Inhibikase Therapeutics' direct or indirect competition across all of the common fundamentals between Inhibikase Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Inhibikase Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Inhibikase Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Inhibikase Therapeutics to competition |
| Fundamentals | Inhibikase Therapeutics | Peer Average |
| Return On Equity | -1.5 | -0.31 |
| Return On Asset | -0.76 | -0.14 |
| Operating Margin | (238.85) % | (5.51) % |
| Current Valuation | 180.34 M | 16.62 B |
| Shares Outstanding | 67.19 M | 571.82 M |
| Shares Owned By Insiders | 10.46 % | 10.09 % |
| Shares Owned By Institutions | 11.62 % | 39.21 % |
| Number Of Shares Shorted | 305.66 K | 4.71 M |
| Price To Book | 26.46 X | 9.51 X |
| Price To Sales | 2,305 X | 11.42 X |
| Revenue | 260.5 K | 9.43 B |
| Gross Profit | (8.26 M) | 27.38 B |
| EBITDA | (19.91 M) | 3.9 B |
| Net Income | (19.03 M) | 570.98 M |
| Cash And Equivalents | 32.21 M | 2.7 B |
| Cash Per Share | 1.28 X | 5.01 X |
| Total Debt | 622 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 7.56 X | 2.16 X |
| Book Value Per Share | 1.77 X | 1.93 K |
| Cash Flow From Operations | (18.09 M) | 971.22 M |
| Short Ratio | 0.17 X | 4.00 X |
| Earnings Per Share | (3.12) X | 3.12 X |
| Target Price | 7.0 | |
| Number Of Employees | 8 | 18.84 K |
| Beta | 1.12 | -0.15 |
| Market Capitalization | 183.44 M | 19.03 B |
| Total Asset | 14.51 M | 29.47 B |
| Retained Earnings | (66.9 M) | 9.33 B |
| Working Capital | 10.77 M | 1.48 B |
| Net Asset | 14.51 M |
Note: Acquisition by Freeman Roy Lester of 30000 shares of Inhibikase Therapeutics at 1.54 subject to Rule 16b-3 [view details]
Inhibikase Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Inhibikase . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Inhibikase Therapeutics Buy or Sell Advice
When is the right time to buy or sell Inhibikase Therapeutics? Buying financial instruments such as Inhibikase Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Inhibikase Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Market Funds Thematic Idea Now
Money Market Funds
Funds or Etfs investing in various types of short-term (less than one year) fixed income instruments of high-quality and liquidity. The Money Market Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Market Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.